AKT1 Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


AKT1 Gene Editing    

AKT1 is a membrane of the AKT kinase family (consist of AKT1, AKT2, and AKT3), which belong to serine/threonine protein kinases. The AKT gene is located on the chromosome at 14q32.33. Phosphorylated AKT regulates many cellular life activities, including metabolism, proliferation, cell survival, and growth, by activating a series of signaling pathways. Growth factors that respond to AKT activity include EGF, IGF. AKT regulates glucose uptake by mediating insulin-induced SLC2A4 / GLUT4 glucose transporter transport to the cell surface. It also regulates the storage of glucose in the form of glycogen. AKT promotes cell survival via the phosphorylation of the apoptosis signal-related kinase. Phosphorylation of "Ser-83" reduces MAP3K5 kinase activity stimulated by oxidative stress, thereby preventing apoptosis. AKT is also a key component that regulates NF-κB-dependent gene transcription and positively regulates the activity of cyclic AMP (cAMP)-responsive element-binding protein (CREB1). Phosphorylation of CREB1 induces the binding of accessory proteins, which are required for the transcription of pro-survival genes.

Akt1 is involved in transvascular migration and metastasis of tumor cells in terms of angiogenesis and endothelial barrier function. In breast cancer cells, AKT1 may act as a metastasis suppressor to inhibit metastasis, while AKT1 can inhibit breast cancer cell migration by enhancing proteasomal degradation of NFAT (activated T cell nuclear factor) transcription factors. Studies have shown that AKT1 can block cell migration through TSC2. The mechanism of action of AKT1 in the pathogenesis of cancer, metastasis and invasion, and other diseases (such as nervous system diseases and diabetes) in different cell types and tissues still needs constant exploration by researchers.

 Pro-tumorigenic effects of AKT in early stages of cancerFigure 1. Pro-tumorigenic effects of AKT in early stages of cancer

AKT1 Gene Editing Service

CRISPR/Cas9 PlatformCB is one of the leading gene editing biotechnology companies and has focused on building efficient systems and procedures to meet the needs and timelines of clients working in the CRISPR/Cas9 gene editing. Our scientists have deep gene editing knowledge and extensive experience in experimental operation and data processing. Based on our platform, CRISPR/Cas9 PlatformCB can help you achieve targeted gene edited including knockout, knockin, or point mutation via CRISPR/Cas9 within shorter turnaround time and lower price.

  • AKT1 Gene Editing Cell Line Generation

Our scientists have extensive experience with >200 distinct cell lines and are very familiar with their culture conditions and genetic backgrounds. CRISPR/Cas9 PlatformCB has successfully implemented AKT1 CRISPR/Cas9 gene editing both easy-to-transfect cell lines and hard-to-transfect cells. Tell us the cell lines your project needs, we will offer you a professional one-stop-shop AKT1 gene editing service from strategy design to final stable cells at a reasonable cost and in a shorter time. Our AKT1 gene editing cell line generation services include:

✧ SgRNA design and synthesis
✧ Transfect the cell line you interest
✧ Select the high expression cell and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of AKT1 by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines, including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

Host cell line: Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.

  • AKT1 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR-Cas9 technology into animal models, which have been recognized by our clients. According to your projects' needs, we will help you obtain targeted gene edited in any animal models you interest via CRISPR/Cas9. We guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower cost. Our AKT1 gene editing animal model generation services include:

➢ AKT1 gene conventional knockout animals
➢ AKT1 gene conditional knockout animals
➢ AKT1 point mutation animals
➢ AKT1 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

Tell us your needs, CRISPR/Cas9 PlatformCB will provide you a professional CRISPR/Cas9 gene editing service from strategy design to final stable cell lines or animal models. With our national-class labs and gene editing scientists from world-class universities, we guarantee our clients the most reliable and efficient research services to best match your research goals and protect your science investment. If you have any project need CRISPR/Cas9 gene editing services, don't hesitate to contact us.

Related Products at CRISPR/Cas9 PlatformCB


  1. Qi Wang. et al. Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer. 2017 Jul 11; 117(2): 159–163.
  2. Alex Toker. Achieving Specificity in Akt Signaling in Cancer. Adv Biol Regul. 2012 Jan; 52(1): 78–87.
  3. Marina Riggio. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Scientific Reports. 2017 March 13; 7: 44244.
For research use only. Not intended for any clinical use.


Verification code